Do elevated hs-CRP and Lp-PLA2 activity indicate inflammation that promotes insulin resistance?

Elevated levels of high-sensitivity C-reactive protein (hs-CRP) and lipoprotein-associated phospholipase A2 (Lp-PLA2) are well-established biomarkers that reflect distinct but overlapping facets of the inflammatory state. While hs-CRP serves as a sensitive measure of systemic inflammation, Lp-PLA2 activity provides a specific window into vascular inflammation, particularly within the arterial wall.

Clinical and mechanistic evidence

• Biomarker Utility: hs-CRP is produced by the liver in response to interleukin-6 (IL-6) and is a validated "risk enhancer" for cardiometabolic disease. Lp-PLA2 is produced by inflammatory cells within atherosclerotic plaques, where it contributes to plaque instability and vascular damage.
• Induction of Insulin Resistance: Systemic and vascular inflammation promotes "metaflammation," a chronic state where pro-inflammatory cytokines like TNF-α and IL-6 circulate at low but persistent levels. Prospective data, such as from the CARDIA study, show that elevated hs-CRP levels independently predict the progression of insulin resistance (measured by HOMA-IR) over time.

Mechanistic explanations

• Kinase Activation: Inflammation triggers intracellular signaling cascades, specifically activating c-Jun N-terminal kinase (JNK) and IkappaB kinase-beta (IKKβ) in metabolic tissues like the liver and muscle.
• IRS Signaling Interference: These kinases catalyze the inhibitory serine phosphorylation (e.g., at Ser307 or Ser312) of Insulin Receptor Substrate-1 (IRS-1).
• Pathway Disruption: Serine phosphorylation of IRS-1 prevents its normal tyrosine phosphorylation by the insulin receptor. This blockade inhibits the recruitment of PI3K and the subsequent activation of the AKT pathway, effectively stopping the translocation of GLUT4 glucose transporters to the cell membrane.

Bottom line

Elevated hs-CRP and Lp-PLA2 activity are reliable indicators of the systemic and vascular inflammation that drives insulin resistance. This occurs through a specific molecular mechanism where inflammatory kinases (JNK and IKKβ) disrupt the insulin receptor/IRS-1 signaling pathway, preventing effective glucose uptake.